{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:11:31Z","timestamp":1759482691867},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1097\/md.0000000000011609","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T20:52:58Z","timestamp":1533243178000},"page":"e11609","source":"Crossref","is-referenced-by-count":9,"title":["Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis"],"prefix":"10.1097","volume":"97","author":[{"given":"Andrea B.V.","family":"Lomonte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e3o C.","family":"Radominski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora M.D.","family":"Marcolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claiton V.","family":"Brenol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano A.F.","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika G.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ermeg L.","family":"Akylbekova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario Ponce","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-44-20210226","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-44-20210226","first-page":"594","article-title":"Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach","volume":"31","author":"Senna","year":"2004","journal-title":"J Rheumatol"},{"key":"R3-44-20210226","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/rheumatology\/keq114","article-title":"Management of rheumatoid diseases: the Brazilian perspective","volume":"49","author":"Cavalcanti","year":"2010","journal-title":"Rheumatology (Oxford"},{"key":"R4-44-20210226","first-page":"44","article-title":"[Diagnosis and therapeutical management offered to rheumatoid arthritis patients in Brazil--rheumatologists\u2019 answers from an assessment questionnaire]","volume":"34","author":"Ferraz","year":"2009","journal-title":"Acta Reumatol Port"},{"key":"R5-44-20210226","first-page":"152","article-title":"2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis","volume":"52","author":"da Mota","year":"2012","journal-title":"Rev Bras Reumatol"},{"key":"R6-44-20210226","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(11)60202-X","article-title":"Successes and failures in the control of infectious diseases in Brazil: social and environmental context, policies, interventions, and research needs","volume":"377","author":"Barreto","year":"2011","journal-title":"Lancet"},{"key":"R7-44-20210226","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0140-6736(09)60792-3","article-title":"Treatment of rheumatoid arthritis: we are getting there","volume":"374","author":"Yazici","year":"2009","journal-title":"Lancet"},{"key":"R8-44-20210226","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4236\/ojra.2013.32011","article-title":"Unmet needs in the treatment of rheumatoid arthritis","volume":"3","author":"Pope","year":"2013","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"R9-44-20210226","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jval.2012.11.007","article-title":"Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment","volume":"16","author":"Augustovski","year":"2013","journal-title":"Value Health"},{"key":"R10-44-20210226","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/eci.12.19","article-title":"Tofacitinib for the treatment of rheumatoid arthritis","volume":"8","author":"Zerbini","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"R11-44-20210226","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R12-44-20210226","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R13-44-20210226","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R14-44-20210226","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R15-44-20210226","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod Rheumatol"},{"key":"R16-44-20210226","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"R17-44-20210226","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"R18-44-20210226","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"R19-44-20210226","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R20-44-20210226","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"R21-44-20210226","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"R22-44-20210226","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"R23-44-20210226","first-page":"1645","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years","volume":"67","author":"Wollenhaupt","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R25-44-20210226","first-page":"512","article-title":"Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib","volume":"55","author":"da Mota","year":"2015","journal-title":"Rev Bras Reumatol"},{"key":"R26-44-20210226","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.reuma.2016.04.010","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: pooled efficacy and safety analyses of Phase 3 and long-term extension studies","volume":"13","author":"Radominski","year":"2017","journal-title":"Reumatol Clin"},{"key":"R27-44-20210226","first-page":"044","article-title":"Safety of tofacitinib in rheumatoid arthritis patients from Latin America and the rest of the world","volume":"25","author":"Citera","year":"2014","journal-title":"Rev Argent Reumatol"},{"key":"R28-44-20210226","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R29-44-20210226","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"R30-44-20210226","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R31-44-20210226","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R33-44-20210226","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R34-44-20210226","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Kourbeti","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R35-44-20210226","first-page":"S1","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"65","author":"Winthrop","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R36-44-20210226","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1590\/S0482-50042011000200005","article-title":"Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results","volume":"51","author":"Titton","year":"2011","journal-title":"Rev Bras Reumatol"},{"key":"R37-44-20210226","first-page":"4","article-title":"2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis","volume":"53","author":"Brenol","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"R39-44-20210226","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res"},{"key":"R40-44-20210226","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","article-title":"Risk of malignancy among patients with rheumatic conditions","volume":"88","author":"Thomas","year":"2000","journal-title":"Int J Cancer"},{"key":"R41-44-20210226","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology (Oxford"},{"key":"R42-44-20210226","first-page":"474","article-title":"2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis","volume":"52","author":"Pereira","year":"2012","journal-title":"Rev Bras Rheumatol"},{"key":"R43-44-20210226","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R44-44-20210226","first-page":"S331","article-title":"Rates of malignancies in patients from 5 rheumatoid arthritis registries across the world","volume":"65","author":"Askling","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R45-44-20210226","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.reuma.2012.09.001","article-title":"Current therapies in rheumatoid arthritis: a Latin American perspective","volume":"9","author":"Burgos-Vargas","year":"2013","journal-title":"Reumatol Clin"},{"key":"R46-44-20210226","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10067-015-3048-1","article-title":"Rheumatoid arthritis in Latin America. Important challenges to be solved","volume":"34","author":"Burgos-Vargas","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R47-44-20210226","doi-asserted-by":"crossref","first-page":"A719","DOI":"10.1016\/j.jval.2013.08.2236","article-title":"Unmet needs and biologic use among patients with rheumatoid arthritis in Brazil","volume":"16","author":"de Renteria","year":"2013","journal-title":"Value Health"},{"key":"R48-44-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R49-44-20210226","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000011609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:18:29Z","timestamp":1620962309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201808030-00044"}},"subtitle":["Pooled efficacy and safety analyses"],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":46,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000011609","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}